Hope for Parkinson’s disease symptoms is found in late-stage drug study
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...
AbbVie's Parkinson's disease drug meets main goal in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...
AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational ...
PharmTech3 天
European Biotechs Unlocking Parkinson’s Disease
Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to ...
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal
Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's ...
Reuters7 天
In paraquat lawsuits, an expert gets bumped (again)
The late November decision by a judge in Contra Costa County follows an earlier order ... science-based review of regulatory ...
Parkinson’s patient died after 52-hour A&E wait meant he didn’t get vital medication
A Parkinson’s patient died after a 52-hour A&E wait meant he did not receive vital medication, an investigation has found ...
AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study -- Update
AbbVie picked up tavapadon as part of its $8.7 billion acquisition of Cerevel Therapeutics earlier this year. Prior to the deal closing, Cerevel had reported a successful Phase 3 study of tavapadon as ...